Pertuzumab rejected for treatment of early breast cancer

Jun 15, 2018

The National Institute for Health and Care Excellence (NICE) rejects pertuzumab for adjuvant treatment of early breast cancer. The draft guidance reports that the drug may not extend patient’s lives and is not cost effective.

Print Page Mail Article